TE

Telix Pharmaceuticals Ltd

  • CIK: 0002007191
  • EIN: 00-0000000
  • Business address: 55 FLEMINGTON ROAD, NORTH MELBOURNE, Australia, 3051

Information

  • Mailing address
    55 FLEMINGTON ROAD, NORTH MELBOURNE, Australia, 3051
  • Phone
    61 3 9093 3855
  • State location
    Australia
  • State of incorporation
    Australia
  • Fiscal year end
    December 31
  • SIC
    2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
  • Filings
    N/A

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd (CIK: 0002007191) is an American company incorporated in the state of Australia. Head office is located at 55 FLEMINGTON ROAD, NORTH MELBOURNE, Australia, 3051. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Telix Pharmaceuticals Ltd is a public company and trade via Over-The-Counter (OTC).

Ownership

Updating!

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Telix Pharmaceuticals Ltd

Filings Format Description Filed/Effective File/Film Number
RW Document

Registration Withdrawal Request

Acc-no: 0001140361-24-030136 (NE Act) Size: 5 KB		 Jun-14-2024

333-279808

241043815
RW Document

Registration Withdrawal Request

Acc-no: 0001140361-24-030120 (NE Act) Size: 10 KB		 Jun-14-2024

333-279471

241043198
8-A12B Document

Form for the registration / listing of a class of securities on a national securities exchange pursuant to section 12(b)

Acc-no: 0001140361-24-029566 (34 Act) Size: 16 KB		 Jun-10-2024

001-42128

241032809
F-1/A Document

Amendment to Registration statement for securities of certain foreign private issuers

Acc-no: 0001140361-24-028932 (33 Act) Size: 8490 KB		 Jun-05-2024

333-279471

241020676
F-6 Document

Registration statement for American Depositary Receipts representing securities of certain foreign private issuers

Acc-no: 0001193805-24-000723 (33 Act) Size: 409 KB		 May-30-2024

333-279808

241000648
F-1 Document

Registration statement for securities of certain foreign private issuers

Acc-no: 0001140361-24-026584 (33 Act) Size: 17474 KB		 May-17-2024

333-279471

24957654
DRS/A Document Acc-no: 0001140361-24-025016 (33 Act) Size: 6346 KB May-09-2024

377-07070

24928212
DRS/A Document Acc-no: 0001140361-24-019882 (33 Act) Size: 7535 KB Apr-15-2024

377-07070

24845188
DRS/A Document Acc-no: 0001140361-24-013335 (33 Act) Size: 6880 KB Mar-15-2024

377-07070

24752248
DRS/A Document Acc-no: 0001140361-24-005348 (33 Act) Size: 4375 KB Feb-02-2024

377-07070

24592146
DRS Document Acc-no: 0001140361-24-003917 (33 Act) Size: 11859 KB Jan-25-2024

377-07070

24563323

Recent 20 filings. View all Telix Pharmaceuticals Ltd filings

Reviews

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Frequently Asked Questions

Tags:

  • Telix Pharmaceuticals Ltd overview
  • Telix Pharmaceuticals Ltd job
  • Telix Pharmaceuticals Ltd stock
  • Telix Pharmaceuticals Ltd ownership
  • Telix Pharmaceuticals Ltd CEO
  • Telix Pharmaceuticals Ltd documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

Bicara Therapeutics Inc.
Update: Aug 23, 2024
Stramsen Biotech, Inc.
Update: May 21, 2024
Rapport Therapeutics, Inc.
Update: May 18, 2024
Contineum Therapeutics, Inc.
Update: Mar 16, 2024
Cuprina Holdings (Cayman) LTD
Update: Mar 08, 2024
APRINOIA Therapeutics Inc.
Update: Jan 27, 2024

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 3593 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 3823 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 3354 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 1503 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 4266 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 3511 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 1244 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 3318 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 2187 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by